Author Archive | Raynovich Rod

Rayno BioBeat 2017 #2: Biotech Breakthrough Rally

2017 Biotech Breakthrough on a Green Screen Day Biotech stocks got a second wind today and the 2017 rally broke through recent tops that have been strong resistance. Our favorite trading pick the XBI soared 4.82% to $70.48 breaking through the September top and 19% up YTD. The large cap IBB went up 2.89% to […]

Continue Reading 0

Biotech ETFs: Fidelity Biotech Fund Outperforms IBB but XBI is Still the Leader

Fidelity Biotech Portfolio (FBIOX) Is Beginning to Show Benefits of Active Management Biotech stocks have outperformed the market YTD despite a bit of a sell-off recently. During the bubblicious momentum days of 2015 when biotech was on a tear major biotech ETFs outperformed mutual funds. After two severe corrections in 2016 the Fidelity Select Biotechnology […]

Continue Reading 0

Rayno Biopharma Portfolio Update: BLUE FMI IBB…Update-1

Update-1… 2/22/17 Dow closed at a record 20,775.6 with energy the big loser, healthcare down 0.19% and NASDAQ flattish. Biotech stocks sold off with the IBB down 0.85% after hitting $296 near a 52 week high last Thursday. XBI was hit harder down 1.77% to $67.79. Large caps were mainly in the red except ALXN,BIIB […]

Continue Reading 2

Biotech Recap: Rally Continues with Strong Tape…Update-1

Update-1 2/16… Profit Taking Day-Momentum Eases IBB,XBI down ~0.65% Large caps mixed: AMGN,GILD,MRK,RHHBY in green; REGN down 2.86%. Alexion (ALXN) down 1.22% on earnings and guidance. Misses on Revs but up 18.5%. Mid Caps in the red: GWPH down 2%; ICPT down 2.26%, RDUS down 6%.Big  Movers Up on News: Agios (AGIO) up 8%, Esperion (ESPR) […]

Continue Reading 0

Large Cap Biopharmaceuticals:Update on Financial Metrics

Top Biopharmaceutical Stocks : Performance and Financial Metrics after 2016 Earnings We have updated the comparison of eight large cap biopharma stocks post 2016 earnings for the period ending 2/10/17. Keep in mind that in January 2016 there was a severe correction with stocks dropping 25-30% with lows being hit in mid-February 2016. But the […]

Continue Reading 0

Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A

Update-1… 1:45p EST Biotech Rally Biogen (BIIB) looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI slight gains. ======== Biotech Rally Takes Levels to January Top IBB up 1% to $284.56, up 7.2% YTD XBI up 1.79% to $67.07, up 13.3% YTD, a new high for 2017 […]

Continue Reading 0

More Drug Pricing Headwinds for Biotech Just as Tape Improves: Update-1 M&A Uptick

Update 2/8/17 12N EST Biotech Stocks Perk Up on M&A Rumors PARP Inhibitor stocks- Clovis Oncology (CLVS) up 3%, Tesaro (TSRO) up 12.5%. IBB and XBI flattish. EXEL up 2.7%. INCY up 1.78%. GWPH up 3.9%. Also Foundation Medicine (FMI) is up over 10% to $24 with no news. GILD down 9.7% to $66: maybe […]

Continue Reading 0

Large Cap Biopharma: January’17 Update-2

2/6/17 1 PM EST Mid-Caps Outperform in 2017 We will update the metrics and performance of “Large Cap Biopharma” after earnings from Gilead Sciences (GILD) and Regeneron (REGN) tomorrow. The XBI is up 11% YTD. The IBB is up 6.3% YTD. Merck (MRK) leads all large cap biotechs up 9.5% YTD. Among mid-caps Incyte (INCY) […]

Continue Reading 0

Biotech Blahs Worsened By Political Distractions…Updates

Update: 1/31/17 Biotechs rallying in midday trading afterTrump meeting. Looks like a good time to add positions like CELG IBB and XBI. Mid-Caps are strong-ALNY TSRO SGEN. Dx and Tools- DHR TMO good earnings. Update: After Close 5P 1/30/17 IBB down 1.35%, XBI down 1.73%, NAZ down 0.83% An associate reminded me that “sentiment” may […]

Continue Reading 0

Notes from J.P.Morgan Conference 2017: Sequencing (NGS) Moves to Toward Clinical Diagnostic Solutions

Outlook and Issues for Application of NGS for Clinical Diagnostics We heard a few presentations on NGS solutions and still think it is an important growth market for clinical diagnostics in oncology, rare diseases transplant medicine and NIPT. Gene sequencing (NGS) can lead to a better understanding of the molecular basis of disease and personalize diagnostics and […]

Continue Reading 0